|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
gptkb:dibenzoxazepine_derivative
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1975
|
|
gptkbp:ATCCode
|
N05AA09
|
|
gptkbp:brand
|
Adasuve
Loxitane
|
|
gptkbp:CASNumber
|
1977-10-2
|
|
gptkbp:chemicalClass
|
tricyclic compound
|
|
gptkbp:contraindication
|
coma
CNS depression
hypersensitivity to loxapine
|
|
gptkbp:eliminationHalfLife
|
4 to 8 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C18H18ClN3O
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
liver
amoxapine
|
|
gptkbp:molecularWeight
|
327.81 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
96.6%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
4017
3879
DB00408
|
|
gptkbp:relatedTo
|
gptkb:clozapine
amoxapine
|
|
gptkbp:riskFactor
|
gptkb:orthostatic_hypotension
seizures
QT prolongation
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
|
|
gptkbp:sideEffect
|
constipation
weight gain
sedation
dry mouth
extrapyramidal symptoms
|
|
gptkbp:synonym
|
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]oxazepine
|
|
gptkbp:UNII
|
GFD2T28MUC
|
|
gptkbp:usedFor
|
schizophrenia
acute agitation
|
|
gptkbp:bfsParent
|
gptkb:Amoxapine
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
loxapine
|